This Company Just Initiated a Quarterly Dividend: Time to Buy?
Regeneron initiated a quarterly dividend per share that looks somewhat attractive. Despite some recent issues, the biotech ...
BioSpace17h
After 10 Years of Hard Work, COUR Treads Into Pharma’s Myasthenia Gravis Territory
COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission ...
Trump threatens 25% tariffs on auto, semiconductor, pharmaceutical imports
President Donald Trump said Tuesday that he will likely impose tariffs of 25% or more on imports of cars, semiconductors and pharmaceutical products. Speaking to reporters at his Mar-a-Lago club in ...
Biogen continues dealmaking buzz with Stoke Therapeutics
Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a ...
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug
Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the latest effort by the biotech company to fill holes in its pipeline.